Supplementary Information

Fenton-like reaction, glutathione reduction, and photothermal ablationbuilt-in hydrogels crosslinked by cupric sulfate for loco-regional cancer therapy

Sungyun Kim^a, Ji-Hye Seo^a, Da In Jeong^a, Mingyu Yang^a, Song Yi Lee^{a,b}, Junmin Lee,^{c,d,e} Hyun-Jong Cho^{a,*}

^aCollege of Pharmacy, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea

^bKangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon,

Gangwon 24341, Republic of Korea

^cDepartment of Bioengineering, University of California-Los Angeles, Los Angeles,

CA 90095, USA

^dCenter for Minimally Invasive Therapeutics (C-MIT) and California NanoSystems Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA ^eTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA

*Corresponding author. Tel.: +82 33 250 6916; fax: +82 33 259 5631.

E-mail address: hjcho@kangwon.ac.kr (H.-J. Cho).



Fig. S1. Injectability test of HC/Cu/ICG8 gel with a single syringe.



Fig. S2. *In vitro* release test of ICG from ICG solution and HC/Cu/ICG8 hydrogel groups. Each point represents mean \pm SD ($n \ge 3$).



Fig. S3. *In vitro* and *in vivo* photothermal efficacy test (at 808 nm wavelength and 0.3 W cm⁻² laser power). Each point represents mean \pm SD (n = 3).



Fig. S4. Cytotoxicity of HC in MDA-MB-231 cells measured by MTS-based assay. Each point represents mean \pm SD ($n \ge 3$).



Fig. S5. NIR laser irradiation time-dependent cell viability data in MDA-MB-231 cells. Each point represents mean \pm SD (n = 4).



Fig. S6. Cellular accumulation efficiency of ICG from ICG solution and HC/Cu/ICG8 groups in MDA-MB-231 cells. Each point represents mean \pm SD (n = 3).



Fig. S7. Copper concentration profiles in plasma following subcutaneous injection of Cu or HC/Cu/ICG8. Each point represents mean \pm SD (n = 4).